Crispr Therapeutics AG revenue
Crispr Therapeutics AG's revenue was $3.5m in fiscal 2025, down 90.6% on the year before. Since fiscal 2015 ($247,000) it has grown at a compound 30.4% a year. Over the last twelve months it was $25.2m.
Revenue history
| Fiscal year | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMSept 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 5 | 41 | 3 | 290 | 1 | 915 | 1 | 371 | 37 | 4 | 25 |
| Growth on the year before | — | +>999% | +693.9% | −92.4% | +>999% | −99.8% | +>999% | −99.9% | +>999% | −89.9% | −90.6% | — |
Where the revenue comes from
| Line of business | Revenue | Share | YoY |
|---|---|---|---|
| Grant | $3.5M | 100.0% | ▲ 51.7% |
| Collaboration Revenue | $0 | 0.0% | ▼ 100.0% |
From Crispr Therapeutics AG's 10-K filed February 12, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Crispr Therapeutics AG | $25.2m | -34.3% | -47.1% |
| Abeona Therapeutics Inc. | $25.5m | -87.7% | 212.0% |
| Janux Therapeutics, Inc. | $24.0m | 5367.0% | 45.7% |
| Stoke Therapeutics, Inc. | $27.6m | -86.2% | 46.1% |
| Monte Rosa Therapeutics, Inc. | $28.7m | -83.9% | — |
| Tonix Pharmaceuticals Holding Corp. | $29.1m | 196.0% | — |
Compare with peers
- Abeona Therapeutics Inc. revenue
- Janux Therapeutics, Inc. revenue
- Stoke Therapeutics, Inc. revenue
- Monte Rosa Therapeutics, Inc. revenue
- Tonix Pharmaceuticals Holding Corp. revenue
Head to head: ABEO vs CRSPCRSP vs JANXCRSP vs STOK
More: Biotechnology stocks compared, Health Care sector, rankings of US companies